EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

DEVELOPMENT OF AN SRF INHIBITOR PEPTIDE FOR THE TREATMENT OF CARDIAC FIBROSIS

Melissa Meschkewitz, Erika Lisabeth, Richard Neubig

Spartan Medical Research Journal · 2024

DOI: 10.51894/001c.122796 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Spartan Medical Research Journal, 2024. Verfasst von Melissa Meschkewitz und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

By Melissa Herschkowitz, Erika Lisabeth & 1 more. Approximately 18.6 million deaths worldwide attributed to cardiovascular disease (CVD) in 2019; US alone the estimated direct and indirect cost of CVD for 2016 to 2017 was $363 billion.

Zitieren

APA

Meschkewitz, M., Lisabeth, E., & Neubig, R. (2024). DEVELOPMENT OF AN SRF INHIBITOR PEPTIDE FOR THE TREATMENT OF CARDIAC FIBROSIS. Spartan Medical Research Journal. https://doi.org/10.51894/001c.122796

Vancouver

Meschkewitz M, Lisabeth E, Neubig R. DEVELOPMENT OF AN SRF INHIBITOR PEPTIDE FOR THE TREATMENT OF CARDIAC FIBROSIS. Spartan Medical Research Journal. 2024. doi:10.51894/001c.122796

BibTeX
@article{Meschkewitz2024,
  author = {Meschkewitz, Melissa and Lisabeth, Erika and Neubig, Richard},
  title = {DEVELOPMENT OF AN SRF INHIBITOR PEPTIDE FOR THE TREATMENT OF CARDIAC FIBROSIS},
  journal = {Spartan Medical Research Journal},
  year = {2024},
  doi = {10.51894/001c.122796}
}
Kostenlos starten →